MedCity News
NOVEMBER 20, 2023
Multiple studies have shown no correlation between R&D costs and the launch price of new drugs though that is an argument often used by drugmakers to prevent a cap on pricing. Still, one way to keep costs low, is for organizations to leverage health technology like AI and improve formulary compliance.
Fierce Pharma
NOVEMBER 21, 2023
With litigation spanning many countries, the COVID-19 vaccine giants remain engaged in a heated patent war. | Moderna pledged to appeal after the European Patent Office ruled one of its patents invalid in the intellectual property battle that spans multiple countries.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
NOVEMBER 21, 2023
Texas AG has sued Pfizer and Tris Pharma for providing adulterated attention-deficit/hyperactivity disorder drug, Quillivant XR, to children.
European Pharmaceutical Review
NOVEMBER 24, 2023
Amgen’s new immunotherapeutic agent Tarlatamab has been shown in a Phase II trial to provide sustained anti-tumour activity in 40 percent of the small cell lung cancer patients. The international DeLLphi-301study was investigated as a new anti-cancer treatment option for patients previously considered to be beyond treatment. Results from the trial were published in the New England Journal of Medicine.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
MedCity News
NOVEMBER 19, 2023
New York Governor Kathy Hochul released a proposed set of cybersecurity regulations that require hospitals to establish new policies and procedures to protect themselves from ever-intensifying cyber threats. The state also put aside $500 million in funding to help hospitals upgrade their technology systems to comply with these new rules.
Fierce Pharma
NOVEMBER 22, 2023
Unable to scale up its manufacturing fast enough to meet the spiraling demand for its GLP-1 weight loss products, Novo Nordisk is employing a new strategy—reducing production of diabetes drug Victo | Unable to scale up its manufacturing fast enough to meet the spiraling demand for its GLP-1 weight loss products, Novo Nordisk is employing a new strategy—reducing production of diabetes drug Victoza to make more Ozempic.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
European Pharmaceutical Review
NOVEMBER 23, 2023
Boehringer Ingelheim is acquiring Swiss biotech T3 Pharmaceuticals AG (T3 Pharma), for up to £406 million (450 million CHF), boosting its immuno-oncology portfolio. The pharmaceutical company will utilise T3 Pharmaceutical’s proprietary bacterial cancer therapy platform that consisting that delivers immune-modulating bioactive proteins to cancer cells and tumour micro-environments.
MedCity News
NOVEMBER 19, 2023
There is a huge opportunity for specialties to play a critical role in complementing primary care and tertiary care by transforming into a sustainable model that is preventive, boundaryless, and one that empowers patients and caregivers.
Fierce Pharma
NOVEMBER 22, 2023
Pfizer, working through a $3.5 billion cost-cutting drive, is not done yet making changes to its workforce in Ireland. | Pfizer's commercial office in Citywest, Dublin, will move to its Ringsend office building, the Irish Independent reports. The moves could end in more job cuts in the company's commercial division.
Evolve Your Success
NOVEMBER 21, 2023
Success in medical sales is not only about knowledge, but also about the application of that knowledge, adapting proactively, and being aware of your impact in the room. In this episode, we have Rob Bahna discuss what truly makes a good medical sales rep. From his early beginnings to climbing the ladder of success, Rob provides a firsthand account of his journey through various leadership positions in medical sales.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
NOVEMBER 21, 2023
Phase III trials of a low carbon version of GSK’s metered dose inhaler, Ventolin (salbutamol), using a next generation, lower carbon propellant, are set to start in 2024. The pharma company stated that if successful, it has the potential to reduce greenhouse gas emissions from use of the inhaler by approximately 90 percent. According to GSK, thirty-five million patients with respiratory conditions globally relying on its metered dose inhaler.
MedCity News
NOVEMBER 23, 2023
With proposed requirements ranging from accessible self-service kiosks to accessible medical equipment, the impact of this new rule will be wide-ranging with financial, operational, and practical consequences.
Fierce Pharma
NOVEMBER 21, 2023
Texas has accused Pfizer and manufacturer Tris Pharma of knowingly providing compromised ADHD medicine to a state Medicaid program for children of low-income families. | In its lawsuit, Texas says the companies knew that deficient manufacturing processes compromised the effectiveness of Quillivant XR. The lawsuit further accuses the companies of manipulating quality-control testing from 2012 to 2018 to ensure samples received passing grades.
Pharmaceutical Technology
NOVEMBER 22, 2023
The funding will go towards the development of the company's four CNS candidates, with Phase II study data readouts expected by early 2025.
European Pharmaceutical Review
NOVEMBER 23, 2023
Following the UK government’s recent announcement of a £520 million funding boost for UK manufacturing, a new Oligonucleotide Manufacturing Innovation Centre of Excellence in Scotland will develop innovative and sustainable techniques for these medicines. According to the Centre for Process Innovation (CPI), oligonucleotides therapeutics use short, chemically synthesised fragments of DNA or RNA to modulate protein expression and ultimately treat the underlying cause of disease.
MedCity News
NOVEMBER 20, 2023
AI may transform health care across the board, but not by itself. It’s a tool, and like any tool, it will work more effectively and more safely in trained hands. As the AI revolution continues to grow, we believe organizations should invest in that training now.
Fierce Pharma
NOVEMBER 21, 2023
Joining drugmakers like AstraZeneca and Novo Nordisk, GSK is making big strides in its quest to clean up its carbon footprint. | GSK plans to start late-stage trials of a low-carbon version of its metered dose inhaler (MDI) Ventolin utilizing a next-generation propellant in 2024. If the new product proves successful, it has the potential to slash greenhouse gas emissions from Ventolin use by roughly 90%.
pharmaphorum
NOVEMBER 23, 2023
US biotech Moderna has completed the installation of its clinical laboratories at its new R&D facility in the UK dedicated to the discovery of new mRNA vaccines and therapeutics, part of a 10-year partnership with the government agreed last year that has been estimated to be worth around £1 billion.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmaVoice
NOVEMBER 20, 2023
Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.
MedCity News
NOVEMBER 21, 2023
Merck’s acquisition of Caraway Therapeutics adds programs for genetically defined neurodegenerative diseases. One of those programs addresses a target that was the focus of a different startup purchased by Merck in 2019.
Fierce Pharma
NOVEMBER 21, 2023
The U.S. Federal Trade Commission isn’t letting up in its effort to crack down on pharma’s alleged misuse of a patent mechanism in the FDA’s regulatory process. | The U.S. Federal Trade Commission isn't letting up in its effort to crack down on pharma's alleged misuse of a patent mechanism in the FDA's regulatory process. And it's Sanofi’s turn to land in the crosshairs.
European Pharmaceutical Review
NOVEMBER 24, 2023
Novo Nordisk is investing over €2.1 billion (16 billion Danish kroner) to expand its production site in Chartres, France, supporting manufacture of its products for serious chronic diseases. Novo Nordisk’s multi-billion facility expansion This financial commitment will greatly strengthen manufacturing capacity, more than doubling the site’s footprint.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
pharmaphorum
NOVEMBER 20, 2023
The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in Germany next year.
MedCity News
NOVEMBER 19, 2023
The German manufacturing site is the latest capital infrastructure move for Eli Lilly, which has already made $11 billion in investments in its global manufacturing capabilities in the past three years. The new site will help Lilly meet strong demand for its diabetes and obesity drugs.
Fierce Pharma
NOVEMBER 20, 2023
After blasting the U.K.’s drug pricing policy, the pharma industry has secured a new government spending deal featuring a higher revenue cap and an innovative drug-friendly rebate mechanism. | After blasting the U.K.’s drug pricing policy, the pharma industry has secured an improved government spending deal. The agreement will double the annual growth rate for prescription meds over the coming years.
European Pharmaceutical Review
NOVEMBER 24, 2023
The European Commission has granted a label expansion of the combination treatment KAFTRIO ® (ivacaftor/tezacaftor/elexacaftor) with ivacaftor, for children aged two to five years old with cystic fibrosis. The treatment from Vertex Pharmaceuticals is indicated for individuals who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator ( CYSTIC FIBROSISTR ) gene.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
Pharmaceutical Technology
NOVEMBER 20, 2023
Takhzyro has been approved for the routine prevention of recurrent hereditary angioedema attacks in patients aged 2 years and older.
MedCity News
NOVEMBER 23, 2023
Proposals targeting misaligned financial incentives, price transparency, and pharmacy access are important and necessary reforms. But the consequences of failing to address pharmacy benefit managers’ use of market power to block competition and extract monopoly profits from payers and consumers will not be limited to drug costs – it will change all of healthcare for generations.
Fierce Pharma
NOVEMBER 22, 2023
Looking to protect its lucrative immunology drug Rinvoq, AbbVie is suing a clutch of generic drug makers that are attempting to market copycat versions of the blockbuster. | In a lawsuit filed in Delaware federal court Monday, AbbVie accused Sandoz, Hetero Labs, Aurobindo Pharma, Intas Pharmaceuticals and Sun Pharmaceutical of trying to sidestep dozens of patents protecting Rinvoq through the next decade.
European Pharmaceutical Review
NOVEMBER 21, 2023
BRUKINSA ® (zanubrutinib) in combination with the anti-CD20 monoclonal antibody obinutuzumab, has been approved by the European Commission (EC) to treat relapsed or refractory follicular lymphoma in individuals who have received at least two prior lines of systemic therapy. The oral treatment is now “the first Bruton’s tyrosine kinase (BTK) inhibitor approved in this indication and has the broadest label of any medicine in its class globally,” stated Dr Mehrdad Mobasher, Chief Medical Officer, H
Expert insights. Personalized for you.
129 
Let's personalize your content